D.E. Shaw & Co
AVTX icon

D.E. Shaw & Co’s Avalo Therapeutics AVTX Stock Holding History

D.E. Shaw & Co’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-72
Closed -$104K – 5178
2022
Q2 		$104K Sell
72
-39
-35% -$52.2K ﹤0.01% 4720
2022
Q1 		$232K Sell
111
-5
-4% -$12.6K ﹤0.01% 4779
2021
Q4 		$570K Buy
116
+56
+93% +$336K ﹤0.01% 4332
2021
Q3 		$378K Buy
60
+53
+757% +$430K ﹤0.01% 4238
2021
Q2 		$63K Buy
+7
New +$58.6K ﹤0.01% 4609

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

D.E. Shaw & Co's AVTX Position: Q3 2022 in Review

D.E. Shaw & Co sold out of Avalo Therapeutics (AVTX) in Q3 2022, closing a stake of 72 shares — an estimated $104K sold.

D.E. Shaw & Co first reported a position in AVTX in Q2 2021 and held it in 5 quarters. The position peaked at $570K in Q4 2021. 18 funds tracked by Wall St. Rank hold AVTX as of Q3 2022.

  • D.E. Shaw & Co reported no remaining Avalo Therapeutics position as of Q3 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 72 Avalo Therapeutics shares in Q3 2022, an estimated $104K.
  • D.E. Shaw & Co first reported a position in Avalo Therapeutics in Q2 2021 and held it in 5 quarters.
  • D.E. Shaw & Co's Avalo Therapeutics position peaked at $570K in Q4 2021.
  • 18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2022.

Based on D.E. Shaw & Co's 13F filing for Q3 2022, filed 14 Nov 2022.